For post-transcriptional regulation, it has been shown that ADAM17 expression level could be post-transcriptionally upregulated by EGFR activation in breast tumor [56] or by phospholipase A(2) treatment in human neuroblastoma SK-N-SH cells [57]. This evidence concerns the gene ADAM17 and breast neoplasm.